A cancer therapy vaccine shows promising results in Phase 1 clinical trials, provoking surprisingly strong anti-tumor immune responses in pancreatic cancer patients. Using technology originating in the Irvine Lab with support from Bridge Project and refined by Elicio Therapeutics, the vaccine hitches a ride on the protein albumin to the lymph nodes, where large populations of immune cells can be taught to attack cancer cells. The Phase 1 vaccine targeted two variations of the cancer gene KRAS. Elicio is currently testing a vaccine that targets seven KRAS mutants, and plans to address other KRAS-driven cancers, such as colorectal and non-small cell lung cancers.